🇮🇳 India Top Stories🌐 Global
India's Generic Drug Makers Scrambling After Trump Threatens 200% Tariff
Times of India·Thursday, 23 July 2026
Indian pharmaceutical companies are in turmoil following Donald Trump's move to impose a 200% tariff on generic medicines exported to the United States. The article notes a two-year window is being discussed, but companies are uncertain about the path forward. India is one of the largest suppliers of generic drugs to the US market.
Why It Matters
India's pharma sector is a major employer and export earner — this tariff threat could hurt company revenues and potentially affect the cost and availability of affordable medicines in the US.
🔒 Potential Impact + source link
Subscribe to unlock the impact analysis and original source for every story.